ARCTURUS THERAPEUTICS HOLDINGS INC. Deferred Revenue
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) had Deferred Revenue of $6.28 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-08-06
- 2026-06-30: Deferred Revenue, Current $6.28M.
- 2026-03-31: Deferred Revenue, Current $7.61M.
- 2025-12-31: Deferred Revenue, Current $8.25M.
- 2025-09-30: Deferred Revenue, Current $6.83M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2026-06-30 | $6.28M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.61M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $8.25M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $6.83M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $11.26M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $12.67M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $19.51M 10-K · filed 2026-03-03 |
| 2024-09-30 | $26.94M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $42.36M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $71.52M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $44.83M 10-K · filed 2025-03-06 |
| 2023-09-30 | $40.77M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $47.96M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $38.49M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $28.65M 10-K · filed 2024-03-14 |
| 2022-09-30 | $4.66M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $26.35M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $53.06M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $43.48M 10-K · filed 2023-03-29 |
| 2021-09-30 | $57.62M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $18.07M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $17.94M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $18.11M 10-K · filed 2022-03-01 |
| 2020-09-30 | $5.70M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $6.77M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $8.10M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $8.40M 10-K · filed 2021-03-01 |
| 2019-09-30 | $11.00M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $9.73M 10-Q · filed 2019-08-14 |
| 2018-12-31 | $6.27M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |